Expression, purification and preliminary X-ray crystallographic studies of the human immunodeficiency virus 1 subtype C protease

被引:9
作者
Coman, Roxana M.
Robbins, Arthur
Goodenow, Maureen M.
McKenna, Robert
Dunn, Ben M. [1 ]
机构
[1] Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA
[2] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA
来源
ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS | 2007年 / 63卷
关键词
D O I
10.1107/S174430910701161X
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Crystals of the human immunodeficiency virus 1 (HIV-1) subtype C protease (PR) complexed with the clinically used inhibitors indinavir (IDV) and nelfinavir (NFV) have been grown in the monoclinic space group P2(1), with mean unit-cell parameters a = 46.7 (+/- 0.1), b = 59.8 (+/- 0.3), c = 87.0 (+/- 0.4) angstrom, beta = 95.2 (+/- 0.5)degrees. The crystals of both complexes have been shown to diffract X-rays to 2.3 angstrom resolution. The diffraction data for the subtype C PR complexes with IDV and NFV were subsequently processed and reduced, with overall R-sym values of 8.4 and 11.4%, respectively. Based on the unit-cell volumes, molecular-replacement results and packing considerations, there are two protease homodimers per crystallographic asymmetric unit in each of the complexes. The data were initially phased using a model based on the crystal structure of HIV-1 subtype B PR; the structures have been determined and further refinement and analysis are in progress. These structures and subsequent studies with other inhibitors will greatly aid in correlating the amino-acid variation between the different HIV PRs and understanding their differential sensitivity and resistance to current drug therapy.
引用
收藏
页码:320 / 323
页数:4
相关论文
共 41 条
[1]   Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G [J].
Abecasis, AB ;
Deforche, K ;
Snoeck, J ;
Bacheler, LT ;
McKenna, P ;
Carvalho, AP ;
Gomes, P ;
Camacho, RJ ;
Vandamme, AM .
AIDS, 2005, 19 (16) :1799-1806
[2]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[3]   Molecular dynamics simulations applied to the study of subtypes of HIV-1 protease common to Brazil, Africa, and Asia [J].
Batista, PR ;
Wilter, A ;
Durham, EHAB ;
Pascutti, PG .
CELL BIOCHEMISTRY AND BIOPHYSICS, 2006, 44 (03) :395-404
[4]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[5]   Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom [J].
Cane, PA ;
de Ruiter, A ;
Rice, P ;
Wiselka, M ;
Fox, R ;
Pillay, D .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (07) :2652-2654
[6]   Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART [J].
Caride, E ;
Hertogs, K ;
Larder, B ;
Dehertogh, P ;
Brindeiro, R ;
Machado, E ;
De Sá, CAM ;
Eyer-Silva, WA ;
Sion, FS ;
Passioni, LFC ;
Menezes, JA ;
Calazans, AR ;
Tanuri, A .
VIRUS GENES, 2001, 23 (02) :193-202
[7]   Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24) :1962-1969
[8]  
*CDC, 2006, ANN PHARMACOTHER, V40, P1708
[9]   Analysis of HIV-1CRF_01 A/E protease inhibitor resistance: Structural determinants for maintaining sensitivity and developing resistance to atazanavir [J].
Clemente, JC ;
Coman, RM ;
Thiaville, MM ;
Janka, LK ;
Jeung, JA ;
Nukoolkarn, S ;
Govindasamy, L ;
Agbandje-McKenna, M ;
McKenna, R ;
Leelamanit, W ;
Goodenow, MM ;
Dunn, BM .
BIOCHEMISTRY, 2006, 45 (17) :5468-5477
[10]  
Collier AC, 1996, ADV EXP MED BIOL, V394, P355